Eli Lilly Unveils Revolutionary Cardiometabolic Health Data at EASD 2026

Eli Lilly and Company is poised to share compelling data about their innovative treatments for cardiometabolic diseases at the upcoming European Association for the Study of Diabetes (EASD) Annual Meeting, taking place from September 28 to October 2, 2026, in Milan, Italy. The presentations will include pivotal findings from their latest studies focusing on Foundayo (orforglipron), retatrutide, and the new combination medication eloraTZP.

In recent clinical trials, such as TRIUMPH-2, retatrutide—a triple hormone receptor agonist—has shown promising results in promoting weight loss and lowering A1C levels among adults dealing with obesity and type 2 diabetes. Participants using retatrutide were able to shed an impressive average of 49.6 lbs (22.5 kg) over an 80-week period, suggesting a profound improvement in weight management for individuals with significant health challenges.

Dr. Kenneth Custer, Executive Vice President and President of Lilly Cardiometabolic Health, expressed the urgency of addressing the global obesity and diabetes crisis during a pre-conference briefing. He noted, "More than a billion people worldwide are living with diabetes or obesity, and meeting their diverse needs requires multiple treatment options based on different mechanisms. We've built our portfolio with a goal of changing the course of the diabetes and obesity epidemics."

Foundayo's Positive Results

Further addressing these chronic health issues, Lilly's ACHIEVE-4 study reaffirmed the safety profile of Foundayo, revealing its potential to enhance cardiovascular health among those with type 2 diabetes. The results indicate that Foundayo not only aids in managing diabetes but also fosters cardiovascular advantages that could transform patient care.

Additionally, Lilly is set to highlight Phase 2 data on eloraTZP, which integrates the selective amylin receptor agonist—eloralintide—with tirzepatide. This follows a significant trend towards developing innovative therapies that combine multiple mechanisms of action, potentially leading to improved outcomes for patients battling obesity and type 2 diabetes.

Symposium and Presentations

In conjunction with the data presentations, Lilly will host a symposium entitled “Changing the Course of Cardiometabolic Disease” on September 28, chaired by Professor Rachel Batterham, Senior Vice President for Medical Innovation and External Engagement in Lilly Cardiometabolic Health. This session marks a celebratory milestone as Lilly commemorates 150 years of innovation, spotlighting early-stage treatments for obesity and type 2 diabetes. Furthermore, discussions will delve into the evolving role of oral therapies and emerging mechanisms that could redefine patient care in this landscape.

Among the key presentations slated for EASD 2026:
1. Retatrutide Symposium (September 30, 2026): Presentation of Phase 3 results from TRIUMPH-2.
2. Mounjaro Symposium (September 30, 2026): Overview of Mounjaro's cardiovascular benefits among adult type 2 diabetes patients.
3. EloraTZP Symposium (September 30, 2026): Data from the exploratory trials combining eloralintide and tirzepatide.
4. Foundayo Symposium (October 1, 2026): Presentation of Phase 3 findings within the ACHIEVE program.

These results are expected to garner attention and stimulate discussions at EASD 2026, as Lilly aims to continue leading advancements in cardiometabolic health treatment strategies. With a focus on holistic care and innovative drug development, Lilly is not only striving to expand treatment options today but is also set to elevate the standards of future patient care in managing cardiometabolic diseases.

As the conference approaches, the medical community eagerly anticipates these pioneering findings that could significantly impact the treatment landscape for millions dealing with obesity and diabetes.